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In this issue of the Journal of Thoracic Oncology, Neri et al.1 present the first report ofpatients who underwent surgical salvage after stereotactic body radiation therapy
(SBRT) for primary or metastatic lung cancer. This report is of value because it shows that
a surgical salvage strategy is feasible for operable patients, and, at least in these seven
patients, the surgery was accomplished without difficulty.
Local recurrence rates after SBRT for stage I lung cancers range between 5 and
15%.2 RTOG 0236 was a prospective multiinstitutional trial that delivered 54 Gy in three
fractions over 7 to 10 days to medically inoperable patients and demonstrated a 3-year
local control rate of 94%.3 Similar to the patients on this Radiation Therapy Oncology
Group (RTOG) study, most patients receiving SBRT to the malignant lesions in the lung
today are not eligible for surgery because of baseline pulmonary function, underlying
cardiac disease, marginal performance status, or a combination of these factors. Therefore,
salvage surgery has not often been a consideration for these patients.
As the data supporting SBRT in lung cancer and limited metastatic disease
continues to mature, the results are becoming more convincing. SBRT offers a very high
rate of local control at a low risk of morbidity. As favorable results emerge, physicians and
patients will weigh SBRT in comparison with surgery. There have been two published
institutional retrospective studies comparing surgery and SBRT for peripheral stage I lung
cancer. One compared wedge resection to SBRT.4 The other study compared lobectomy
to SBRT.5 Both indicate that the cause-specific survival may be similar between these two
treatment strategies but that overall survival was higher for surgical patients. Both also
illustrate the need for randomized prospective phase III comparisons in unselected
patients. Currently, there are two ongoing randomized trials attempting to compare
surgical lobectomy with SBRT for patients with stage I lung cancer. The Radiosurgery or
Surgery for Operable Early Stage I Lung Cancer Study is open through the Dutch Lung
Cancer Research Group. The primary objectives are to compare local and regional tumor
control, quality of life, and treatment costs between lobectomy and SBRT at 2 and 5 years.
In the United States, Accuray Inc. is sponsoring an International Randomized Study to
Compare Cyberknife Stereotactic Radiotherapy with Surgical Resection in Stage I
non-small cell lung cancer. This study is limited to centers that use the Cyberknife
radiosurgery system. The primary end point is to compare 3-year overall survival for
patients treated with lobectomy versus SBRT. Neither trial is meeting accrual expecta-
tions. A third trial is being opened jointly by the American College of Surgeons Oncology
Group and the RTOG that will compare sublobectomy SBRT for patients who are at too
high a risk for a lobectomy (ACOSOG4099/RTOG 1021). Results from any of these trials
will take 5 to 10 years to be reported. Until then, we will be left with prospective phase
I/II data and/or individual preference on which to base our recommendations for patients.
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If the trend of encouraging data continues, the number of
patients who decide to be treated with SBRT rather than
surgery is likely to increase.
What can be done for a patient who experiences a local
failure after SBRT to the lung? In patients who are not eligible
for surgery, that choice has been limited to chemotherapy,
further radiation therapy, or observation. There are minimal to
no data on which to base a treatment choice in this situation.
Whatever the choice, the outcome is expected to be suboptimal.
For operable patients who have had a local failure after SBRT,
up until now an uncommon situation, the optimal treatment
strategy is surgical salvage. The article by Neri et al. indicates
that surgical salvage is feasible, can be done with low morbidity,
and should be a consideration for these patients. Meanwhile,
more experience is necessary to verify their findings.
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